India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now
You may also be interested in...
Sun Pharma Chief’s 1% Interest In Natco Sends India’s Grapevine Into M&A Overdrive
Sun Pharma chairman’s purchase of stock in Natco is not likely to be a deal precursor.
United And Divided: Natco's Patent Challenge On Revlimid Leads Dr. Reddy's To Up Its Pitch
MUMBAI - Natco Pharma's patent challenge earlier this month over Celgene's blockbuster multiple myeloma drug Revlimid (lenalidomide) has led India's Dr. Reddy's Labs to fast-track its own development of the product, which was brought under a restricted distribution plan by U.S. FDA due to its risky profile
United And Divided: Natco's Patent Challenge On Revlimid Leads Dr. Reddy's To Up Its Pitch
MUMBAI - Natco Pharma's patent challenge earlier this month over Celgene's blockbuster multiple myeloma drug Revlimid (lenalidomide) has led India's Dr. Reddy's Labs to fast-track its own development of the product, which was brought under a restricted distribution plan by U.S. FDA due to its risky profile